Meijer Fleur, Cornelissen Petra, Sie Corina, Wagemans Michel, Mars Anja, Hobma Tiny, Niesters Marieke, Dahan Albert, Koopman J Seppe, Steegers Monique Ah
Department of Anesthesiology, Leiden University Medical Centre, Leiden, the Netherlands.
Department of Anesthesiology Pain and Palliative Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands.
J Pain Res. 2018 May 24;11:987-992. doi: 10.2147/JPR.S160091. eCollection 2018.
The sublingual sufentanil tablet system (SSTS) is a novel hand-held patient-controlled analgesia device developed for treatment of moderate-to-severe postoperative pain. Here we present the first results of its clinical use.
Adult patients undergoing major surgery in five hospitals in the Netherlands received the SSTS for postoperative pain relief as part of multimodal pain management that further included paracetamol and a nonsteroidal anti-inflammatory drug (NSAID). The following variables were collected: postoperative pain scores using the 11-point numerical rating score (NRS) at rest, number of tablets used, occurrence of nausea, and patient satisfaction scores.
We included 280 patients in the study; the majority underwent laparoscopic abdominal (49%) or orthopedic (knee replacement) surgery (34%). The median NRS was 3.5 (interquartile range 2.3-4.0) on the day of surgery, 3.3 (2.3-4.0) on the first postoperative day, and 2.8 (2.0-4.0) on the second postoperative day; pain scores did not differ between surgery types. Mean number of tablets used was 19 (range 0-86). Nausea occurred in 34% of patients, more often in women (45% vs 19%). Overall satisfaction was high in 73% of patients. Satisfaction was correlated with pain relief (<0.001) and inversely correlated with occurrence of nausea (=0.01).
In this data set obtained under real-life conditions we show that the SSTS effectively managed postoperative pain in abdominal and orthopedic surgeries. Future studies should determine patient populations that benefit most from the SSTS, assess the added values versus intravenous patient-controlled analgesia, and determine the pharmacoeconomics of the system.
舌下舒芬太尼片剂系统(SSTS)是一种新型手持式患者自控镇痛装置,用于治疗中重度术后疼痛。在此,我们展示其临床应用的首批结果。
荷兰五家医院接受大手术的成年患者接受SSTS用于术后疼痛缓解,作为多模式疼痛管理的一部分,该管理还包括对乙酰氨基酚和非甾体抗炎药(NSAID)。收集了以下变量:静息时使用11点数字评分量表(NRS)的术后疼痛评分、使用的片剂数量、恶心的发生率以及患者满意度评分。
我们纳入了280例患者进行研究;大多数患者接受了腹腔镜腹部手术(49%)或骨科(膝关节置换)手术(34%)。手术当天的NRS中位数为3.5(四分位间距2.3 - 4.0),术后第一天为3.3(2.3 - 4.0),术后第二天为2.8(2.0 - 4.0);不同手术类型的疼痛评分无差异。平均使用的片剂数量为19片(范围0 - 86片)。34%的患者出现恶心,女性更常见(45%对19%)。73%的患者总体满意度较高。满意度与疼痛缓解相关(<0.001),与恶心的发生呈负相关(=0.01)。
在这个在现实生活条件下获得的数据集里,我们表明SSTS在腹部和骨科手术中有效管理了术后疼痛。未来的研究应确定最能从SSTS中获益的患者群体,评估与静脉自控镇痛相比的附加价值,并确定该系统的药物经济学。